GSK Receives the MHRA’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma
Shots:
- MHRA has approved Blenrep + BorDex & PomDex in MM pts with ≥1 prior therapy incl. Revlimid; review ongoing in 14 markets incl. US (PDUFA: Jul 23, 2025), EU, Canada, Japan [priority review (PR)], China (PR for DREAMM-7), & Switzerland (PR for DREAMM-8)
- Approval was based on P-III (DREAMM-7 & DREAMM-8) trials assessing Blenrep (2.5mg/kg, IV, Q3W) + BorDex vs Darzalex + BorDex in 494 pts & Blenrep + PomDex vs Velcade + PomDex in 302 pts, respectively
- DREAMM-7 met its 1EP of improved PFS (mPFS: 36.6 vs 13.4mos.), reducing death risk by 42% at 39.4mos. mFU & depicting a 3yr. OS rate of 74% vs 60%, while in DREAMM-8 (21.8mos. mFU), mPFS was not reached vs 12.7mos.; data was presented at ASCO 2024 & published in The NEJM
Ref: GSK | Image: GSK
Related News:- GSK Reports the US FDA’s BLA Acceptance of Blenrep (Belantamab Mafodotin) Regimen for Treating R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
